Overview

Phase 1b Study Investigating the Association of NP137 With mFOLFIRINOX in Locally Advanced Pancreatic Ductal Adenocarcinoma

Status:
Not yet recruiting

Trial end date:
2024-11-01

Target enrollment:

Participant gender:

Summary

The study will assess the safety of the association of NP137 with the standard of care mFOLFIRINOX in the treatment of locally advanced pancreatic ductal adenocarcinoma.The study drug which is tested is the NP137 in association with mFOLFIRINOX to allow a better tumor response as well as better survival outcomes with an acceptable safety.

Phase:

Phase 1

Details

Lead Sponsor:

University Hospital, Grenoble

Collaborator:

NETRIS Pharma

Treatments:

Calcium
Irinotecan
Leucovorin
Levoleucovorin
Oxaliplatin